Clinical Trials Browser

Phase 3 × Not yet recruiting × zanubrutinib × Clear all

NCT07321652 2026-01-07

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Phase 3 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell